Gene: BRCA2 ×
Source: ALL
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs11571818
rs11571818
BRCA2
C 0.700 GeneticVariation GWASCAT Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. 27197191

2016
dbSNP: rs11571833
rs11571833
BRCA2
T 0.720 GeneticVariation GWASCAT Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. 27197191

2016
dbSNP: rs11571833
rs11571833
BRCA2
0.720 GeneticVariation BEFREE The K3326X variant was associated with breast (ORw = 1.28, 95% CI = 1.17 to 1.40, P = 5.9x10(-) (6)) and invasive ovarian cancer</span> (ORw = 1.26, 95% CI = 1.10 to 1.43, P = 3.8x10(-3)). 26586665

2016
dbSNP: rs11571833
rs11571833
BRCA2
0.720 GeneticVariation BEFREE However, a stop-gain mutation, K3326* (rs11571833), confers risk of lung cancer and cancers of the upper-aero-digestive tract but only a modest risk of breast or ovarian cancer. 29767749

2018
dbSNP: rs144848
rs144848
BRCA2
0.040 GeneticVariation BEFREE Moreover, stratified analyses by the cancer type and source of control observed significantly increased risk associated with BRCA2 N372H in subgroups with ovarian cancer, non-Hodgkin lymphoma and population-based controls, but not breast cancer or hospital-based controls. 25348552

2014
dbSNP: rs144848
rs144848
BRCA2
0.040 GeneticVariation BEFREE The HH genotype of the nonconservative amino acid substitution polymorphism N37</span>2H in the BRCA2 gene was reported to be associated with a 1.3- to 1.5-fold increase in risk of both breast and ovarian cancer. 15668505

2005
dbSNP: rs144848
rs144848
BRCA2
0.040 GeneticVariation BEFREE The subgroup analysis for serous cancer subgroup showed that the significant association could be detected under recessive model (OR = 1.38, 95% CI, 1.01-1.89, P = 0.04) and under homozygote comparison (OR = 1.46, 95% CI, 1.06-2.01, P = 0.022).Our meta-analysis suggests that the N372H polymorphism is associated with susceptibility of ovarian cancer. 26496279

2015
dbSNP: rs144848
rs144848
BRCA2
0.040 GeneticVariation BEFREE We have examined whether BRCA2 N372</span>H or common amino acid-changing polymorphisms in BRCA1 predispose to ovarian cancer. 14555511

2003
dbSNP: rs1555283322
rs1555283322
BRCA2
G 0.700 CausalMutation CLINVAR

dbSNP: rs1566215870
rs1566215870
BRCA2
A 0.700 CausalMutation CLINVAR

dbSNP: rs1566221377
rs1566221377
BRCA2
CT 0.700 CausalMutation CLINVAR

dbSNP: rs1566228017
rs1566228017
BRCA2
T 0.700 CausalMutation CLINVAR

dbSNP: rs1566231316
rs1566231316
BRCA2
A 0.700 CausalMutation CLINVAR

dbSNP: rs1566232230
rs1566232230
BRCA2
T 0.700 CausalMutation CLINVAR

dbSNP: rs1566233171
rs1566233171
BRCA2
T 0.700 CausalMutation CLINVAR

dbSNP: rs1566244975
rs1566244975
BRCA2
C 0.700 CausalMutation CLINVAR

dbSNP: rs1566260318
rs1566260318
BRCA2
C 0.700 GeneticVariation CLINVAR

dbSNP: rs276174868
rs276174868
BRCA2
C 0.700 CausalMutation CLINVAR

dbSNP: rs397507419
rs397507419
BRCA2
CA 0.700 CausalMutation CLINVAR

dbSNP: rs397507591
rs397507591
BRCA2
A 0.700 CausalMutation CLINVAR

dbSNP: rs397507608
rs397507608
BRCA2
A 0.700 CausalMutation CLINVAR

dbSNP: rs41293497
rs41293497
BRCA2
G 0.700 CausalMutation CLINVAR

dbSNP: rs55854959
rs55854959
BRCA2
0.010 GeneticVariation BEFREE Identification of a novel BRCA1 nucleotide 4803delCC/c.4684delCC mutation and a nucleotide 249T>A/c.130T>A (p.Cys44Ser) mutation in two Greenlandic Inuit families: implications for genetic screening of Greenlandic Inuit families with high risk for breast and/or ovarian cancer. 20437199

2010
dbSNP: rs587781506
rs587781506
BRCA2
A 0.700 CausalMutation CLINVAR

dbSNP: rs786203853
rs786203853
BRCA2
CT 0.700 CausalMutation CLINVAR